Very recently, data from the RxPONDER trial (ClinicalTrials.gov, ID: NCT01272037, Access date: 1 February 2021), investigating the predictive potential of Oncotype DX RS in patients with HR-positive, HER2-negative breast cancer and 1 to 3 involved axillary lymph nodes were presented [93]. The gene discussed is ERBB2; the disease is breast cancer.